Why the study?
Managing hypertriglyceridemia-induced acute pancreatitis is challenging due to the need for rapid triglyceride reduction below 500mg/dL (5.645 mmol/L).
Does tafolecimab (a PCSK9 inhibitor) reduce triglyceride levels and improve symptoms in severe hypertriglyceridemia-induced acute pancreatitis refractory to conventional therapy?
Case Report (n=1)
No
Does tafolecimab (a PCSK9 inhibitor) reduce triglyceride levels and improve symptoms in severe hypertriglyceridemia-induced acute pancreatitis refractory to conventional therapy?
Answers are grounded in this paper and cite their sources.
PCSK9 inhibition with tafolecimab rapidly and safely reduced extreme hypertriglyceridemia and resolved acute pancreatitis in a patient failing conventional therapy, suggesting a potential novel therapeutic application.
INTRODUCTION: Managing hypertriglyceridemia-induced acute pancreatitis (HTG-AP) can be challenging, particularly due to the need for rapid triglyceride reduction to below 500mg/dL (5.645 mmol/L). CASE REPORT: This is a case describing a 39-year-old female patient who presented to the Emergency Department with acute abdominal pain resulting from severe HTG-AP. However, under conventional therapy with oral lipid-lowering drugs, the triglyceride levels remained uncontrolled. Oral moderate-intensity statins could not only reduce low-density lipoprotein cholesterol (LDLc) by 25%-50%. However, increasing the dose could not further reduce blood lipids while increasing the risk of liver damage. After the administration of proprotein convertase subtilisin/ kexin type 9 inhibitor (PCSK9i), the triglyceride levels were well controlled with no additional side effects, and the symptoms of the patients were completely relieved. CONCLUSION: In cases of unsatisfactory lipid control under conventional therapy, PCSK9i may offer a viable option for managing HTG-AP.
No takes yet. Share an insight, caveat, or question.
Qi et al. (2025) conducted a case report in Hypertriglyceridemia-induced acute pancreatitis (HTG-AP) (n=1). Tafolecimab (PCSK9 inhibitor) was evaluated on Triglyceride level reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: